GP (HK) Announces the Positive Profit Alert, The Consolidated Net Profit Attributable to Owners of the Company for the First Half of 2021 is Expected to Increase Not Less Than 50%
(July 27, 2021 - Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that for the six months ended 30 June 2021, it is expected that the consolidated net profit attributable to owners of the Company recorded an increase of not less than 50% compared with the corresponding period in 2020 (the corresponding period in 2020: approximately HK$719 million).
The reason for financial results maintained growing in a good shape is mainly attributable to: 1) the Group continuously optimizes the profit structure, continuously develops the Group’s strategy in the development of innovative and barrier medicines and puts more efforts in the sales of innovative high barrier products and high profit margin products, resulting the overall sales revenue is expected to increase by not less than 40% as compared with the same period of last year; and 2) fair value change of investment portfolio in listed companies contributes increment of investment income of the Group.
The Board of China Grand Pharmaceutical and Healthcare Holdings Limited, commented, “In the first half of 2021, the world entered the era of pandemic recovery, and economic growth has returned stable. In this context, the Group rapidly resumed production and operation, accurately grasped market opportunities, continuously expanded business coverage and enriched innovative product pipeline, which helps the Group ultimately achieved excellent results. Looking ahead, the Group will continue to adopt the strategy of ‘global expansion and dual-cycle operation’ and keep focusing on market demand. With the vision of internationalization and technological innovation, the Group will also constantly explore new impetus for continuously growth, give full play to its comprehensive strengths, increase its investment in the world-class innovative products and advanced technologies, enrich the Group’s product pipeline and expand business coverage, in turn strengthen competitiveness and bring greater returns for our shareholders and investors.”